← Back to Clinical Trials
Recruiting NCT06330818

NCT06330818 Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06330818
Status Recruiting
Phase
Sponsor University Hospital Tuebingen
Condition Moyamoya Disease
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-07-01
Primary Completion 2027-07-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
MRIH2 15O PET/CTBiosampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-07-01 with a primary completion date of 2027-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aim of this study is to improve patient care in Moyamoya Patients by improving Imaging technologies and aiming to identify factors involved in disease progression. Main tasks are: * Analysis of CO2-triggered BOLD fMRI for analysis of cerebral hemodynamics in comparison to H2 15O PET/CT * Analysis of longitudinal changes of contrast enhancement in vessel-wall imaging and correlation of disease activity with biosampling * Definition of a standardized recommendation for pre- and postoperative imaging of Moyamoya patients

Eligibility Criteria

Inclusion Criteria: * Patients with suspicion of Moyamoya Disease * Patients able to understand the study and to give their informed consent Exclusion Criteria: * Cerebral vascular disease caused by atherosclerosis * Vasculitis * Contraindications to MRI * Contraindications to PET/CT * Pregnancy * Inability to give informed consent * Renal insufficiency

Contact & Investigator

Central Contact

Constantin Roder, Prof. Dr., MD

✉ constantin.roder@med.uni-tuebingen.de

📞 0049-7071290

Frequently Asked Questions

Who can join the NCT06330818 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Moyamoya Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06330818 currently recruiting?

Yes, NCT06330818 is actively recruiting participants. Contact the research team at constantin.roder@med.uni-tuebingen.de for enrollment information.

Where is the NCT06330818 trial being conducted?

This trial is being conducted at Tübingen, Germany.

Who is sponsoring the NCT06330818 clinical trial?

NCT06330818 is sponsored by University Hospital Tuebingen. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology